Knight Therapeutics (TSE:GUD) Reaches New 52-Week High – Here’s What Happened

Shares of Knight Therapeutics Inc. (TSE:GUD) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as C$9.51 and last traded at C$9.46, with a volume of 62054 shares changing hands. The stock had previously closed at C$9.48.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group set a C$9.50 price objective on Knight Therapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, Knight Therapeutics presently has a consensus rating of “Buy” and a consensus target price of C$9.50.

Knight Therapeutics Stock Performance

The stock has a market cap of C$930.74 million, a PE ratio of 158.00, a P/E/G ratio of -1,013.50 and a beta of -0.14. The firm has a 50-day simple moving average of C$8.08 and a 200-day simple moving average of C$6.83. The company has a quick ratio of 1.79, a current ratio of 2.32 and a debt-to-equity ratio of 8.86.

Knight Therapeutics (TSE:GUD) last posted its earnings results on Thursday, May 7th. The company reported C$0.13 earnings per share (EPS) for the quarter. The firm had revenue of C$147.59 million for the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%. Equities analysts forecast that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.